Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta 1a - Faron Pharmaceuticals

Next Previous
Drug Profile

Interferon beta 1a - Faron Pharmaceuticals

Alternative Names: FP-1201; FP-1201-lyo; IFN beta-1a; Interferon beta-1a - Faron Pharmaceuticals; MR11A8; Recombinant human interferon beta-1a - Faron Pharmaceuticals; Traumakine

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Faron Pharmaceuticals
  • Developer Faron Pharmaceuticals; Maruishi Pharmaceutical
  • Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
  • Mechanism of Action Immunostimulants; Interferon beta-1a replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome; Acute lung injury
  • New Molecular Entity No
  • Available For Licensing Yes - Adult respiratory distress syndrome

Highest Development Phases

  • No development reported Acute kidney injury; Cytokine release syndrome; Reperfusion injury; Vascular injuries
  • Discontinued Abdominal aortic aneurysm; Adult respiratory distress syndrome; Brain injuries; Spinal cord injuries

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for preclinical development in Acute kidney injury in Finland (IV)
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Cytokine release syndrome in Finland (IV)
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Reperfusion-injury in Finland (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top